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InﬂammationThe wnt signaling pathway plays important roles in development and inmany diseases. Recently several reports
suggest that non-canonicalWnt proteins contribute to the inﬂammatory response in adult animals. However, the
effects ofWnt proteins on virus-inducedmyocarditis have not been explored. Here, we investigated the effect of
Wnt11 protein in a model of myocarditis induced by coxsackievirus B3 (CVB3) using recombinant adeno-
associated virus 9 (rAAV9). The effect of Wnt11 gene therapy on a CVB3-induced myocarditis model was exam-
ined usingmale BALB/cmice. Mice received a single intravenous injection of either rAAV9-Wnt11 or rAAV9-LacZ
2 weeks before intraperitoneal administration of CVB3. Intravenous injection of the rAAV9 vector resulted in ef-
ﬁcient, durable, and relatively cardiac-speciﬁc transgene expression. Survival was signiﬁcantly greater among
rAAV9-Wnt11 treatedmice than amongmice treatedwith rAAV9-LacZ (87.5% vs. 54.1%, P b 0.05).Wnt11 expres-
sion also reduced the inﬁltration of inﬂammatory cells, necrosis of the myocardium, and suppressed the mRNA
expression of inﬂammatory cytokines. This is the ﬁrst report to show that Wnt11 expression improves the sur-
vival of mice with CVB3-induced myocarditis. AAV9-mediated Wnt11 gene therapy produces beneﬁcial effects
on cardiac function and increases the survival of mice with CVB3-induced myocarditis through the suppression
of both inﬁltration of inﬂammatory cells and gene expression of inﬂammatory cytokines.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Viral myocarditis is an important cause of human morbidity
and mortality for which speciﬁc and effective therapy is lacking. It
has been commonly associated with cardiotropic viruses, such as
coxsackievirus, with histological inﬂammation of the myocardium [1,
2]. It is also one of the primary causes of acute heart failure and may
progress to dilated cardiomyopathy and chronic heart failure [3–6].
Viral myocarditis has been investigated in the murine model of
coxsackievirus B3 (CVB3)-inducedmyocarditis. Studies in these models
have revealed that direct viral injury and the subsequent immune
response in the acute to subacute phase determine the severity of
viral myocarditis [5,7]. The inﬂammatory response has the beneﬁcial
effect of viral clearance; however, an overly prolonged immune reaction
can cause further damage to salvaged cardiomyocytes. CVB3-inducedbinant adeno-associatedvirus 9;
s, left ventricular end-systolic
ventricular shortening fraction.
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. This is an open access article undermyocarditis results in excessive Th1 immune responses that proved to
play a critical pathogenetic role in the initiation and progression of
CVB3 myocarditis [8,9].
Myocarditis is a diseasewith variable clinicalmanifestations ranging
from asymptomatic electrocardiogram abnormality to cardiogenic
shock or fatal outcome. Supportive care is the ﬁrst line of treatment
for acute myocarditis due to the lack of speciﬁc therapy. Fulminant
myocarditis shows severe hemodynamic compromise requiring high
dose vasopressor support or mechanical circulatory support, which
was identiﬁed in 10% ofmyocarditis patients [6]. These patients typical-
ly have severe global left ventricular dysfunction. On the other hand,
only 45% of patients with acute (nonfulminant) myocarditis survived
without having received heart transplantation for 11 years [6]. This
report suggests that speciﬁc therapies to modulate the inﬂammation in-
duced bymyocarditis should be investigated.More than 20 treatment tri-
als for myocarditis or inﬂammatory cardiomyopathy have been reported
using immunosuppressive, immunomodulating, anti-inﬂammatory, or
immunoadsorption therapies. Immunosuppressive therapy using pred-
nisolone, azathioprine, or cyclosporine failed to improve survival inmyo-
carditis patients [10]. Speciﬁc therapies that can improve prognosis in
conjunction with supportive treatment are expected to be developed.
The Wnt glycolipoproteins are best characterized as regulators
of cell proliferation, cell polarity, and cell-fate determination duringthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathway have also been linked to hematological malignancies
(e.g., acute and chronic myeloid leukemia, acute lymphoblastic leuke-
mia, multiple myeloma) and to inﬂammatory diseases such as type 2
diabetes, in adults [11–14]. Within the immune system, the canonical
Wnt-β-catenin signaling appears to have an important role in the self-
renewal of hematopoietic stem cells and progenitor cells, in T- and
B-cell development, in peripheral T-cell activation, and in the matura-
tion of dendritic cells [15–17], whereas non-canonical signaling by
Wnt5a may counteract canonical Wnt signaling to inhibit B- and
T-cell development. Wnt5a also regulates the inﬂammatory response
by modulating interleukin production in monocytes and macrophages
[18,19]. Additionally, Wnt11, which regulates the development of
heart and kidney through the non-canonical Wnt signaling pathway,
suppresses inﬂammation in intestinal epithelial cells [20–22]. Collective-
ly, these reports suggest thatWnt proteins participate in the inﬂammato-
ry response and consequently, that patients recovering from heart
diseases with inﬂammation might beneﬁt from therapies that alter Wnt
signaling.
Myocarditis is one of the representative heart diseases that inﬂam-
mation is a major constituent of the disease. Acute viral-induced myo-
carditis is accompanied by severe inﬂammation of the infected heart,
with high mortality. Wnt11, which regulates heart development in em-
bryonic stage and can modulate inﬂammation in adult organs, is one of
intriguing candidates for the therapy of heart diseases with inﬂamma-
tion, especially virus-induced myocarditis. We explored the possibility
that Wnt11 gene therapy exerts a therapeutic effect in a CVB-induced
model of myocarditis.
2. Materials and methods
2.1. Coxsackievirus B3 (CVB3)
CVB3 (Nancy strain) was a kind gift fromDr. Y. Seko (Asahi Life Foun-
dation, Tokyo, Japan). It was grown in cultures of Vero cell (ATCC), then
tittered by plaque assay and stored at−80 °C [23]. Aliquots from the
same stock were used for all animals.
2.2. Mouse model of viral myocarditis
Six-week-old male BALB/c mice were purchased from SLC Co. Ltd.
(Nagoya, Japan). Mice were inoculated intraperitoneally with
1 × 106 PFU of CVB3 in 100 μl PBS on day 0 to induce acute viral myo-
carditis. Mice were observed for spontaneous death until day 14.
Mice were weighed on days 0, 4, 7, 10, and 14 after CVB3 infection
and average body weight was calculated. Surviving mice were exam-
ined by echocardiography on days 0, 4, 7, 10, and 14 post-CVB3 infec-
tion. All experimental procedures and animal-care protocols were
approved by the Institutional Animal Care and Use Committee of
Nagoya University.
2.3. Production of recombinant virus
cDNA encoding mouse Wnt11 (Open Biosystems, Inc.) was
subcloned into the EcoRI/SalI sites of a pAAV-MCS vector using the
AAV Helper-Free System (Agilent Technologies) to create pAAV-
Wnt11. pAAV2/9 containing AAV2 rep and AAV9 capsid genes was
kindly provided by the Penn Vector Core (University of Pennsylvania
School of Medicine).
The rAAV9 viruses were produced by the triple transfectionmethod,
using AAV293 cells (Agilent Technologies) [24,25]. The pAAV-LacZ
(Agilent Technologies) and pAAV-Wnt11 plasmids were co-transfected
with the pHelper and the pAAV2/9 plasmids into AAV293 cells
using the CaPO4 method (Agilent Technologies) according to the
manufacturer's instructions. At 48 h post-transfection the cells were
lysed by freeze–thaw cycles and Benzonase (SIGMA) was added to aﬁnal concentration of 200 μm/ml, before incubating at 37 °C for 1 h. The
extracted recombinant AAV9 viruses were puriﬁed by two rounds of ce-
sium chloride (CsCl) isopycnic gradient centrifugation. Virus sample was
dialyzed using a 10,000 MWCO Slide-A-Lyzer Dialysis Cassette (Thermo
Scientiﬁc) and phosphate-buffered saline containing 5% sorbitol. The
titer was determined by quantitative polymerase chain reaction (PCR)
using primers for the cytomegalovirus (CMV) promoter.
2.4. AAV9 infection
For assessment of gene expression, 3 × 1011-genome copy (GC)
doses of rAAV9-LacZ were administered from the tail vein of mice. For
experiments performed in the CVB3-induced myocarditis model,
3 × 1011-GCdoses of AAV9-LacZ or rAAV9-Wnt11 in 150 μl PBSwere ad-
ministered 2 weeks before CVB3 infection via tail vein injection.
2.5. Cardiac functional assessments
Cardiac function was evaluated with an echocardiographic system
(ACUSON Sequoia c512, SIEMENS). Mice in subgroups were anesthe-
tized with pentobarbital and examined by echocardiography for left
ventricular end-diastolic dimensions (LVEDd), left ventricular end-
systolic dimensions (LVEDs), left ventricular ejection fraction (LVEF)
and left ventricular shortening fraction (FS) on days 0, 4, 7, 10, and 14
after CVB3 infection by two independent observers in a blindedmanner.
LVEFwas calculated by the following equation; LVEF= {Left ventricular
end-diastolic volume (LVEDV)− left ventricular end-systolic volume
(LVESV)} / (LVEDV) × 100 (%). LVEDV and LVESV were estimated by
Teichholz formula: (7.0/2.4 + D) (D3), where D is the internal dimen-
sion of left ventricular end-diastole and end-systole measured from
M-mode tracing.
2.6. Histopathological evaluation
Micewere killed on days 4, 7, 10, and 14 post-CVB3 infection. Hearts
were embedded in O.C.T. compound, snap-frozen in liquid nitrogen, and
cut into 7-μm sections. Sections were stained with hematoxylin and
eosin to evaluate the level of inﬂammation. Evidence of myocarditis
was evaluated according to a 6-tier scoring system: grade 0, no inﬂam-
mation; grade 1, cardiac inﬁltration in up to 5% of the cardiac sections;
grade 2, 6–10%; grade 3, 11–30%; grade 4, 31–50%; and grade 5, N50%
[26].
To evaluate CD45, CD68, CD3 and Ly6G expression, sections
were ﬁxed with cold acetone and then stained with anti-CD45 (BD
Pharmingen), anti-CD68 (Bio-Rad), anti-CD3 (Abcam) and anti-Ly6G
(BD Pharmingen) primary antibodies and Alexa-Fluor 488 or Alexa-
Fluor 594 secondary antibodies (Invitrogen Corporation); nuclei were
counterstained with DAPI.
Fibrosis was evaluated by treating sections with 0.05% picrosirius
red (Direct Red 80; Sigma-Aldrich Corp.) solution for 1 h as previously
described [27].
2.7. Real-time, reverse transcription polymerase chain reaction (RT-PCR),
and gene array analyses
RNA was isolated from frozen, homogenized organ tissues using
ULTRA-TURRAX T8, as instructed by the manufacturer. For quantitative
RT-PCR analyses, total RNAwas reverse transcribedwith a ReverTra Ace
qPCR RTMasterMixwith gDNARemover (TOYOBOCo. Ltd.), and ampli-
ﬁcationwas performed on aMx3000pQPCR system (Stratagene). Prim-
er sequences are reported in the Supplementary Table. The relative
expression of each mRNA was calculated by the comparative threshold
cycle method and normalized to β-actin RNA expression. Data were
shown as a relative value for WT heart without any virus infection.
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Mice were anesthetized with an intraperitoneal injection of sodium
pentobarbital (100mg/kg) on day 14. Blood sampleswere collected im-
mediately. Blood samples were centrifuged (1500 rpm for 10 min) and
then supernatants were stored as serum at−80 °C used for analysis.
Mouse IFN-γ was measured by commercially available enzyme-linked
immunosorbent assay (Enzo Life Sciences).
2.9. Statistical analysis
Survival was summarized via Kaplan–Meier analysis and evaluated
for signiﬁcance with the log-rank test. Other results are presented as
mean±SEM. Comparisons between two groupswere evaluated for sig-
niﬁcance with the Student's t-test and measurements obtained in theControl
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Fig. 1. The rAAV9 vector induces robust, durable, and cardiac-speciﬁc gene expression. 3.0 × 1
(A) LacZ expression was identiﬁed in the hearts of mice sacriﬁced 1–4 weeks after treatment b
in the liver, skeletal muscle, and kidney at 2 weeks after treatment of 3.0 × 1011 GC of rAAV9-
2 weeks after rAAV9-Wnt11 injection via RT-PCR and normalized to β-actin. n = 4.same animal atmultiple time points were evaluated via repeatmeasure
analysis. A P value less than 0.05 was considered signiﬁcant.3. Results
3.1. Systemic rAAV9-Wnt11 administration leads to persistent, cardiac-
speciﬁc gene expression
The efﬁciency, duration, speciﬁcity, and dose-dependence of rAAV9-
mediated transduction was evaluated by injecting rAAV9-LacZ into the
tail vein of BALB/cWTmice andmonitoring LacZ expression for 4weeks.
X-gal-stained sections of cardiac tissue indicated that cardiomyocytes
expressed LacZ in the heart and that a substantial proportion of
cardiomyocytes expressed the transduced gene within 2 weeks ofWeek 4
Week 1
Kidneyscle
day 14
01
011 GC of AAV9-LacZ expression vector was injected into the tail vein of BALB/c WT mice.
y 3.0 × 1011 GC of rAAV9-LacZ via X-gal staining; scale bar = 200 μm. (B) LacZ expression
LacZ (scale bar = 200 μm). (C) Gene expression of Wnt11 in heart tissue was measured
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that in the liver, skeletal muscle, and kidney (Fig. 1B).
Next gene expression of Wnt11 in the heart tissue was evaluated
2 weeks after rAAV9-Wnt11 administration and compared to control
sample. Systemic administration of rAAV9-Wnt11 resulted in strong
gene expression of Wnt11 in the heart tissue (Fig. 1C).
Moreover, we checked RNA expression of endogenous Wnt11 after
CVB3 infection byRT-PCR. Virus infection of CVB3 induced no signiﬁcant
increase of Wnt11 for 28 days (Supp. Fig. 2).
3.2. Systemic rAAV9-Wnt11 administration protects mice from CVB3-
induced myocarditis
To evaluate the effect of Wnt11 gene expression on CVB3-induced
myocarditis, we injected 3.0 × 1011 GC of rAAV9-Wnt11 or rAAV9-
LacZ 2 weeks before CVB3 infection. More than 40% of mice treated
with rAAV9-LacZ died within 14 days post-infection, while mice receiv-
ing rAAV9-Wnt11 treatment showed a signiﬁcantly higher 14-day
survival rate at 87.5% (P= 0.0127) (Fig. 2A).
Body weight is a parameter reﬂecting the overall health status of
mice. Mice were weighed on days 4, 7, 10, and 14 after CVB3 infection
and average body weight was calculated. Mice treated with rAAV9-
LacZ developed hypophagia after CVB3 infection, resulting in body
weight loss during the course of the study, while mice treated with
rAAV9-Wnt11 showed a steady increase in body weight gain reﬂecting
a better general condition (Fig. 2B).
To determine whether rAAV9-Wnt11 treatment enhanced cardiac
function after CVB3 infection, echocardiographic assessments were per-
formed on days 0, 4, 7, 10, and 14 after CVB3 infection. There was no0
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Fig. 2.Wnt11 expression improves survival, cardiac function, and preserves the general conditi
coding forWnt11(rAAV9-Wnt11) or LacZ (rAAV9-LacZ) expressionwas injected into the tail ve
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end-diastolic dimensions (LVEDd), left ventricular end-systolic dimensions (LVEDs), left ventri
on days 4, 7, 10, and 14 after CVB3 infection. (D) Data of day 10. n = 6 for each time points. ⁑Pdifference in LVEDd between either groups. However, compared to
rAAV9-LacZ treated mice, LVEDs was signiﬁcantly lower and LVEF and
FS were signiﬁcantly higher in mice treated rAAV9-Wnt11 on days 7,
10 and 14 post CVB3 infection (Fig. 2C, D).
3.3. Administration of rAAV9-Wnt11 reduces inﬁltration of inﬂammatory
cells during CVB3-induced myocarditis
Moderate to severe inﬂammation as well as widespread degenera-
tion and necrosis of the myocardium were observed in rAAV9-LacZ
treated mice on days 10 and 14 after CVB3 infection. On the other
hand, fewer inﬁltrating inﬂammatory cells were observed in rAAV9-
Wnt11 treated mice, resulting in an improved pathological score of
the heart tissue (Fig. 3A, B). Furthermore, sections stained for expres-
sion of the inﬂammatorymarker CD45 indicated that prolonged inﬂam-
mation was present in the heart tissue of mice treated with rAAV9-LacZ
until 14 days after CVB3 infection, while rAAV9-Wnt11 administration
was associated with fewer inﬂammatory cells in the heart tissue after
day 7. The difference in the cardiacmRNA level of CD45 between groups
also supports this phenomenon (Fig. 4A, B).
We also examined the inﬁltration of macrophages, T cells and neu-
trophils by immunohistochemistry on day 14 after CVB3 infection to
evaluate what inﬂammatory cells are affected by Wnt11. Surprisingly,
CD68 positivemacrophages, CD3 positive T cells and Ly6G positive neu-
trophils were dramatically suppressed in the heart treated with rAAV9-
Wnt11 (Fig. 5). These data indicate that Wnt11 expression can reduce
inﬁltration of inﬂammatory cells globally. Fibrosiswhich can be induced
by inﬂammation was not enhanced in both samples of LacZ andWnt11
groups on day 14 (Supp. Fig. 1).18
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Fig. 3.Wnt11 expression reduced inﬂammation and necrosis of the myocardium post-
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Fig. 4.Wnt11 expression reduces inﬁltration of inﬂammatory cells into the myocardium
post-CVB3 infection. Mice in subgroups were sacriﬁced on days 4, 7, 10, and 14 post-
CVB3 infection. (A) Inﬂammatory cells were identiﬁed by staining sections for expression
of the inﬂammatory cell marker CD45 (green). Nuclei were counter-stained with DAPI
(scale bar = 200 μm). (B) The mRNA level of CD45 at every time point was measured
via RT-PCR and normalized to β-actin; n = 6 for each time points. *P b 0.05.
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expression of inﬂammatory cytokines during CVB3-induced myocarditis
To determine how rAAV9-Wnt11 administration affects the cytokine
response in cardiac tissue post-CVB3 infection, cardiac cytokine mRNA
expression was evaluated by RT-PCR on days 4, 7, 10, and 14 after CVB3
infection. CardiacmRNA levels of IL-1β, IL-6, and IFN-γwere signiﬁcantly
decreased in rAAV9-Wnt11 treated mice compared to those of mice
treated with rAAV9-LacZ. Similarly, the mRNA expression of IP-10,
which plays a critical role on CVB3-induced myocarditis, was also signif-
icantly suppressed in rAAV9-Wnt11 treated mice (Fig. 6A).
Concentration of IFN-γ, which is a cytokine that is critical for innate
and adaptive immunity against viral was examined in blood samples
14 days after CVB3 infection using enzyme-linked immunosorbent
assay. rAAV9-Wnt11 treatment showed a tendency to suppress the
concentration of IFN-γ in circulating blood compared to rAAV9-LacZ
treatment (Supp. Fig. 3).4. Discussion
Viral infections like coxsackievirus B3 are the most commonly
indentiﬁed cause of myocarditis in developed countries [28]. CVB3
infection can lead to viral myocarditis through a direct virus-mediated
reaction and autoimmune-mediated responses [29,30]. In the acute
phase, direct injury of cardiomyocytes due to virus infection can be
induced in conjunction with secondary injury of cardiomyocytes bythe inﬂammation through innate immune cells such as dendritic cells
(DCs), natural killer (NK) cells and macrophages [31]. During the
same phase, the expression of various cytokines, such as IL-1β, IL-6,
TNF-α, IFN-γ, and IP10, can be upregulated in the heart [31,32]. These
cytokines play a crucial role in the defense against virus infection [33,
34], however, overly robust expression of these cytokines can cause se-
vere inﬂammation and widespread necrosis of the myocardium [35].
Although treatment of myocarditis should be focused on the causal
pathophysiology, speciﬁc treatment options for viral myocarditis are
not established. For patients who deteriorate despite optimal medical
treatment with cardiogenic shock due to acute ﬂuminant myocarditis,
mechanical circulatory support may be required to bridge the patient
to recovery or heart transplantation. On the other hand, investigational
treatment options using immunosuppressive or anti-inﬂammatory
agents aswell as immunoadsorption therapy have been reported. How-
ever, immunosuppressive therapy has not been shown to be effective as
routine treatment for acute myocarditis [36].
Wnt signaling is not only essential in T- and B-cell development but
may also have an important role in the activation of immune cells in the
periphery. T-cell migration and the induction/maintenance of a regula-
tory immune response are partly controlled byWnt signaling [16]. Both
the canonical and the non-canonical Wnt pathways may inﬂuence the
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Fig. 5.Wnt11 expression reduces inﬁltration of macrophages, T-cells and neutrophils into
the myocardium post-CVB3 infection. Mice in subgroups were sacriﬁced on days 14 post-
CVB3 infection. Macrophages, T-cells and neutrophils were identiﬁed by staining sections
for expression of CD68, CD3 and Ly6G, respectively (scale bar = 100 μm).
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Given its widespread importance in the immune system and hemato-
poiesis, both activators and inhibitors of the Wnt pathway could be
used to treat pathological conditions with inﬂammation.
Recombinant adeno-associated virus has become increasing com-
mon as a vector for use in human clinical trials [38]. The popularity of
AAV vectors reﬂects the appreciation of the long-term gene expression
in post mitotic cells and the relative lack of deleterious immune re-
sponse. To date over a hundred naturally occurring primate AAVs have
been reported. Among them, rAAV9 has a high natural afﬁnity for myo-
cardium [25]. Our results conﬁrmed that rAAV9-mediated gene delivery
is efﬁcient, cardiac-speciﬁc, and durable: gene expression was robust in
the heart, much lower in the liver, skeletal muscle and kidney. These
data show that rAAV9 is suitable vector to examine the effects of
Wnt11 in virus-induce model of myocarditis.
Here, we investigated the effect of rAAV9-mediated Wnt11 gene
therapy on a myocarditis model induced by CVB3. rAAV9-Wnt11 treat-
ed mice showed a signiﬁcantly improved 14-day survival rate at 87.5%
in contrast to the low survival rate of 54.1% in the rAAV9-LacZ treated
mice. Wnt11 expression was also associated with signiﬁcant improve-
ments in cardiac function and appeared to reduce the inﬁltration of in-
ﬂammatory cells into the heart. Interestingly, diverse populations of
inﬂammatory cells including macrophages, T-cells and neutrophils
were affected byWnt11. Moreover, the expression of inﬂammatory cy-
tokines such as IL-1β, IL-6, and IFN-γ was signiﬁcantly suppressed in
rAAV9-Wnt11 treated mice compared to rAAV9-LacZ treated mice
after day 7 of CVB3 infection. IP-10 expression was also dramatically
suppressed in rAAV9-Wnt11 treated mouse. IP-10 is considered to be
a Th-1 mediated chemokine that plays a critical role in CVB3-induced
myocarditis [39–41]. Therefore, suppression of the expression of IP-10
can lead to a reduction in chemokine-directed inﬂammation and the
resultant myocardial injury [42]. Collectively, Wnt11 gene expressionrAAV-LacZ
rAAV-Wnt11
IP
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suppressing the inﬂammatory response. However, we cannot deny the
possibility that cardiomyocytesweredirectly protectedbyWnt11protein
against inﬂammation, though it is difﬁcult to distinguish between direct
effect and indirect effect through the suppression of inﬂammation.
In this study, we clearly showed the beneﬁcial effects of Wnt11 in
virus-induced myocarditis. We expect to be able to apply a modiﬁed
rAAV9 vector with the property of rapid gene expression or recombi-
nant protein of Wnt11 with high bioactivity for human Wn11 therapy
in the near future. Our data proved the concept that Wnt11 has beneﬁ-
cial therapeutic effects in virus-induced myocarditis.
In conclusion, this is the ﬁrst evidence for the importance of Wnt11
signal in CVB3-induced myocarditis. AAV9-mediatedWnt11 gene ther-
apy protects against viral myocarditis, as documented by a dramatic re-
duction in the histopathologic evidence of myocardial injury and gene
expression of inﬂammatory cytokines, and improved survival of mice
with CVB3-induced myocarditis. Wnt11 therapy could be a promising
novel approach for treating CVB3-induced myocarditis.
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